Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Is Regeneron's Stock in Trouble After This FDA Rejection?
Motley Fool
Thu, 07/6/23 - 10:15 am
Tags:
Regeneron, Eylea, FDA
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Fierce Pharma
Tue, 06/27/23 - 10:24 pm
Tags:
Regeneron, Eylea, FDA
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Fierce Biotech
Thu, 06/22/23 - 10:41 pm
Tags:
Aslan, Dupixent, Japan, eczema, Sanofi, Regeneron, eblasakimab
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Medical Marketing and Media
Tue, 06/6/23 - 11:13 am
Tags:
Dupixent, Sanofi, Regeneron, DTC advertising
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
Tags:
FDA, Albireo Pharma, Aldeyra Therapeutics, Alvotech, Amneal Pharmaceuticals, Argenx, ARS Pharmaceuticals, AstraZeneca, Bayer, Bio-Thera Solutions, Biogen, BioMarin Pharmaceutical, Bristol Myers Squibb, Eisai, Eton Pharmaceuticals, F2G, Fabre-Kramer Pharmaceuticals, Fresenius, GSK, Intercept Pharmaceuticals, Ipsen, Ironwood Pharmaceuticals, Merck, Novaliq, Pfizer, Regeneron, Roche, Sanofi, Sarepta Therapeutics, Shionogi, Swedish Orphan Biovitrum, Takeda, Teva Pharmaceutica, UCB Pharma
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
Fierce Biotech
Thu, 05/25/23 - 08:49 pm
Tags:
ASCO 2023, Regeneron, advanced melanoma, fianlimab
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Mon, 05/22/23 - 10:16 am
Tags:
Sanofi, Regeneron, COPD, Dupixent
Supreme Court rules against Amgen bid to revive cholesterol drug patents
KFGO/Reuters
Thu, 05/18/23 - 11:24 am
Tags:
Supreme Court, Amgen, Sanofi, Regeneron, patents, Repatha, legal
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Medical Marketing and Media
Wed, 05/17/23 - 10:48 pm
Tags:
Amgen, Horizon Therapeutics, FTC, Regeneron, antitrust, M&A, Leonard Schleifer
A blockbuster year could be building
EP Vantage
Wed, 05/10/23 - 09:55 am
Tags:
AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Horizon Therapeutics, Merck, Moderna Therapeutics, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi
Revenues down for Moderna, up for Regeneron in Q1
Medical Marketing and Media
Thu, 05/4/23 - 10:28 am
Tags:
Moderna Therapeutics, Regeneron, earnings
Chronic hives: Four major clinical trials to watch in 2023
Clinical Trials Arena
Wed, 05/3/23 - 11:53 am
Tags:
chronic hives, chronic urticaria, clinical trials, Sanofi, Regeneron, dupilumab, Amgen, tezepelumab, Allakos, lirentelimab, Celldex Therapeutics, barzolvolimab
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Fri, 04/28/23 - 10:08 am
Tags:
Alnylam, Regeneron, clinical trials, Alzheimer's disease, ALN-APP
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
Wed, 04/26/23 - 05:50 pm
Tags:
AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead Sceinces, JNJ, Merck, Pfizer, Regeneron, patents, activists
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Wed, 04/26/23 - 05:44 pm
Tags:
Roche, Vabysmo, Eylea, earnings, Regeneron
After massive equity awards, Regeneron's top 2 execs collected smaller pay packages in 2022
Fierce Pharma
Mon, 04/24/23 - 11:18 pm
Tags:
Regeneron, exective pay, George Yancopoulos, Len Schleifer
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
Tags:
R&D, AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, GSK, JNJ, Merck, Merck KGaA, Moderna Therapeutics, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, UCB, Vertex Pharmaceuticals
REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma
Onc Live
Tue, 04/18/23 - 09:49 am
Tags:
Regeneron, AACR, REGN5459, relapsed or refractory multiple myeloma
The end of an era: Regeneron chairman Roy Vagelos to retire after 29-year run
Fierce Pharma
Mon, 04/17/23 - 12:01 pm
Tags:
Regeneron, Roy Vagelos, Len Schleifer, George Yancopoulos
Regeneron expects $56M IPR&D charge tied to cell therapy pact
Fierce Biotech
Mon, 04/10/23 - 04:53 pm
Tags:
Regeneron, earnings, R&D, Sonoma Biotherapeutics

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.